102 results on '"Okell L"'
Search Results
2. The role of antimalarial treatment in the elimination of malaria
- Author
-
Gosling, R.D., Okell, L., Mosha, J., and Chandramohan, D.
- Published
- 2011
- Full Text
- View/download PDF
3. Author Correction: Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’ (Nature, (2020), 584, 7821, (425-429), 10.1038/s41586-020-2488-1)
- Author
-
Lavezzo, E., Franchin, E., Ciavarella, C., Cuomo-Dannenburg, G., Barzon, L., Del Vecchio, C., Rossi, L., Manganelli, R., Loregian, A., Navarin, N., Abate, D., Sciro, M., Merigliano, S., De Canale, E., Vanuzzo, M. C., Besutti, V., Saluzzo, F., Onelia, F., Pacenti, M., Parisi, S. G., Carretta, G., Donato, D., Flor, L., Cocchio, S., Masi, G., Sperduti, A., Cattarino, L., Salvador, R., Nicoletti, M., Caldart, F., Castelli, G., Nieddu, E., Labella, B., Fava, L., Drigo, M., Gaythorpe, K. A. M., Ainslie, K. E. C., Baguelin, M., Bhatt, S., Boonyasiri, A., Boyd, O., Coupland, H. L., Cucunuba, Z., Djafaara, B. A., van Elsland, S. L., Fitzjohn, R., Flaxman, S., Green, W. D., Hallett, T., Hamlet, A., Haw, D., Imai, N., Jeffrey, B., Knock, E., Laydon, D. J., Mellan, T., Mishra, S., Nedjati-Gilani, G., Nouvellet, P., Okell, L. C., Parag, K. V., Riley, S., Thompson, H. A., Unwin, H. J. T., Verity, R., Vollmer, M. A. C., Walker, P. G. T., Walters, C. E., Wang, H., Wang, Y., Watson, O. J., Whittaker, C., Whittles, L. K., Xi, X., Brazzale, A. R., Toppo, S., Trevisan, M., Baldo, V., Donnelly, C. A., Ferguson, N. M., Dorigatti, I., and Crisanti, A.
- Published
- 2021
4. Report 41: The 2020 SARS-CoV-2 epidemic in England: key epidemiological drivers and impact of interventions
- Author
-
Knock, E, Whittles, L, Lees, J, Perez Guzman, P, Verity, R, Fitzjohn, R, Gaythorpe, K, Imai, N, Hinsley, W, Okell, L, Rosello, A, Kantas, N, Walters, C, Bhatia, S, Watson, O, Whittaker, C, Cattarino, L, Boonyasiri, A, Djaafara, A, Fraser, K, Fu, H, Wang, H, Xi, X, Donnelly, C, Jauneikaite, E, Laydon, D, White, P, Ghani, A, Ferguson, N, Cori, A, Baguelin, M, and Medical Research Council (MRC)
- Subjects
Coronavirus ,England ,COVID19 ,COVID-19 ,United Kingdom ,Real Time Modelling - Abstract
England has been severely affected by COVID-19. We fitted a model of SARS-CoV-2 transmission in care homes and the community to regional 2020 surveillance data. Only national lockdown brought the reproduction number below 1 consistently; introduced one week earlier in the first wave it could have reduced mortality by 23,300 deaths on average. The mean infection fatality ratio was initially ~1.3% across all regions except London and halved following clinical care improvements. The infection fatality ratio was two-fold lower throughout in London, even when adjusting for demographics. The infection fatality ratio in care homes was 2.5-times that in the elderly in the community. Population-level infection-induced immunity in England is still far from herd immunity, with regional mean cumulative attack rates ranging between 4.4% and 15.8%.
- Published
- 2020
- Full Text
- View/download PDF
5. Report 34: COVID-19 infection fatality ratio: estimates from seroprevalence
- Author
-
Brazeau, N, Verity, R, Jenks, S, Fu, H, Whittaker, C, Winskill, P, Dorigatti, I, Walker, P, Riley, S, Schnekenberg, RP, Heltgebaum, H, Mellan, T, Mishra, S, Unwin, H, Watson, O, Cucunuba Perez, Z, Baguelin, M, Whittles, L, Bhatt, S, Ghani, A, Ferguson, N, Okell, L, and Medical Research Council (MRC)
- Subjects
Coronavirus ,COVID19 ,COVID-19 - Abstract
The infection fatality ratio (IFR) is a key statistic for estimating the burden of coronavirus disease 2019 (COVID-19) and has been continuously debated throughout the current pandemic. Previous estimates have relied on data early in the epidemic, or have not fully accounted for uncertainty in serological test characteristics and delays from onset of infection to seroconversion, death, and antibody waning. After screening 175 studies, we identified 10 representative antibody surveys to obtain updated estimates of the IFR using a modelling framework that addresses the limitations listed above. We inferred serological test specificity from regional variation within serosurveys, which is critical for correctly estimating the cumulative proportion infected when seroprevalence is still low. We find that age-specific IFRs follow an approximately log-linear pattern, with the risk of death doubling approximately every eight years of age. Using these age-specific estimates, we estimate the overall IFR in a typical low-income country, with a population structure skewed towards younger individuals, to be 0.23% (0.14-0.42 95% prediction interval range). In contrast, in a typical high income country, with a greater concentration of elderly individuals, we estimate the overall IFR to be 1.15% (0.78-1.79 95% prediction interval range). We show that accounting for seroreversion, the waning of antibodies leading to a negative serological result, can slightly reduce the IFR among serosurveys conducted several months after the first wave of the outbreak, such as Italy. In contrast, uncertainty in test false positive rates combined with low seroprevalence in some surveys can reconcile apparently low crude fatality ratios with the IFR in other countries. Unbiased estimates of the IFR continue to be critical to policymakers to inform key response decisions. It will be important to continue to monitor the IFR as new treatments are introduced. The code for reproducing these results are available as a R Research Compendium on Github: `mrc-ide/reestimate_covidIFR_analysis`.
- Published
- 2020
6. Report 32: Targeting interventions to age groups that sustain COVID-19 transmission in the United States
- Author
-
Monod, M, Blenkinsop, A, Xi, X, Herbert, D, Bershan, S, Tietze, S, Bradley, V, Chen, Y, Coupland, H, Filippi, S, Ish-Horowicz, J, McManus, M, Mellan, T, Gandy, A, Hutchinson, M, Unwin, H, Vollmer, M, Weber, S, Zhu, H, Bezancon, A, Ferguson, N, Mishra, S, Flaxman, S, Bhatt, S, Ratmann, O, Ainslie, K, Baguelin, M, Boonyasiri, A, Boyd, O, Cattarino, L, Cooper, L, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Djaafara, A, Dorigatti, I, Van Elsland, S, Fitzjohn, R, Gaythorpe, K, Geidelberg, L, Green, W, Hamlet, A, Jeffrey, B, Knock, E, Laydon, D, Nedjati Gilani, G, Nouvellet, P, Parag, K, Siveroni, I, Thompson, H, Verity, R, Walters, C, Donnelly, C, Okell, L, Bhatia, S, Brazeau, N, Eales, O, Haw, D, Imai, N, Jauneikaite, E, Lees, J, Mousa, A, Olivera Mesa, D, Skarp, J, Whittles, L, Medical Research Council (MRC), and Abdul Latif Jameel Foundation
- Subjects
Coronavirus ,COVID19 ,COVID-19 ,USA - Abstract
Following inial declines, in mid 2020, a resurgence in transmission of novel coronavirus disease (COVID-19) has occurred in the United States and parts of Europe. Despite the wide implementaon of non-pharmaceucal inter-venons, it is sll not known how they are impacted by changing contact paerns, age and other demographics. As COVID-19 disease control becomes more localised, understanding the age demographics driving transmission and how these impact the loosening of intervenons such as school reopening is crucial. Considering dynamics for the United States, we analyse aggregated, age-specific mobility trends from more than 10 million individuals and link these mechaniscally to age-specific COVID-19 mortality data. In contrast to previous approaches, we link mobility to mortality via age specific contact paerns and use this rich relaonship to reconstruct accurate trans-mission dynamics. Contrary to anecdotal evidence, we find lile support for age-shis in contact and transmission dynamics over me. We esmate that, unl August, 63.4% [60.9%-65.5%] of SARS-CoV-2 infecons in the United States originated from adults aged 20-49, while 1.2% [0.8%-1.8%] originated from children aged 0-9. In areas with connued, community-wide transmission, our transmission model predicts that re-opening kindergartens and el-ementary schools could facilitate spread and lead to considerable excess COVID-19 aributable deaths over a 90-day period. These findings indicate that targeng intervenons to adults aged 20-49 are an important con-sideraon in halng resurgent epidemics, and prevenng COVID-19-aributable deaths when kindergartens and elementary schools reopen.
- Published
- 2020
- Full Text
- View/download PDF
7. Report 31: Estimating the burden of COVID-19 in Damascus, Syria: an analysis of novel data sources to infer mortality under-ascertainment
- Author
-
Van Elsland, S, Watson, O, Alhaffar, M, Mehchy, Z, Whittaker, C, Akil, Z, Ainslie, K, Baguelin, M, Bhatt, S, Boonyasiri, A, Boyd, O, Brazeau, N, Cattarino, L, Charles, G, Ciavarella, C, Cooper, L, Coupland, H, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Djaafara, A, Donnelly, C, Dorigatti, I, Eales, O, Nascimento, F, Fitzjohn, R, Flaxman, S, Forna, A, Fu, H, Gaythorpe, K, Green, W, Hamlet, A, Hauck, K, Haw, D, Hayes, S, Hinsley, W, Imai, N, Jeffrey, B, Johnson, R, Jorgensen, D, Knock, E, Laydon, D, Lees, J, Mellan, T, Mishra, S, Nedjati Gilani, G, Nouvellet, P, Okell, L, Olivera Mesa, D, Pons Salort, M, Ragonnet-Cronin, M, Siveroni, I, Stopard, I, Thompson, H, Unwin, H, Verity, R, Vollmer, M, Volz, E, Walters, C, Wang, H, Wang, Y, Whittles, L, Winskill, P, Xi, X, Ferguson, N, Beals, E, Walker, P, Anonymous Authors, Medical Research Council (MRC), and Abdul Latif Jameel Foundation
- Subjects
Coronavirus ,Syria ,COVID19 ,COVID-19 - Abstract
The COVID-19 pandemic has resulted in substantial mortality worldwide. However, to date, countries in the Middle East and Africa have reported substantially lower mortality rates than in Europe and the Americas. One hypothesis is that these countries have been ‘spared’, but another is that deaths have been under-ascertained (deaths that have been unreported due to any number of reasons, for instance due to limited testing capacity). However, the scale of under-ascertainment is difficult to assess with currently available data. In this analysis, we estimate the potential under-ascertainment of COVID-19 mortality in Damascus, Syria, where all-cause mortality data has been reported between 25th July and 1st August. We fit a mathematical model of COVID-19 transmission to reported COVID-19 deaths in Damascus since the beginning of the pandemic and compare the model-predicted deaths to reported excess deaths. Exploring a range of different assumptions about under-ascertainment, we estimate that only 1.25% of deaths (sensitivity range 1% - 3%) due to COVID-19 are reported in Damascus. Accounting for under-ascertainment also corroborates local reports of exceeded hospital bed capacity. To validate the epidemic dynamics inferred, we leverage community-uploaded obituary certificates as an alternative data source, which confirms extensive mortality under-ascertainment in Damascus between July and August. This level of under-ascertainment suggests that Damascus is at a much later stage in its epidemic than suggested by surveillance reports, which have repo. We estimate that 4,340 (95% CI: 3,250 - 5,540) deaths due to COVID-19 in Damascus may have been missed as of 2nd September 2020. Given that Damascus is likely to have the most robust surveillance in Syria, these findings suggest that other regions of the country could have experienced similar or worse mortality rates due to COVID-19.
- Published
- 2020
8. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults
- Author
-
Ward, H, Atchison, C, Whitaker, M, Ainslie, K, Elliot, J, Okell, L, Redd, R, Ashby, D, Donnelly, C, Barclay, W, Darzi, A, Cooke, G, Riley, S, and Elliot, P
- Abstract
Background England, UK has experienced a large outbreak of SARS-CoV-2 infection. As in USA and elsewhere, disadvantaged communities have been disproportionately affected. Methods National REal-time Assessment of Community Transmission-2 (REACT-2) seroprevalence study using self-administered lateral flow immunoassay (LFIA) test for IgG among a random population sample of 100,000 adults over 18 years in England, 20 June to 13 July 2020. Results Completed questionnaires were available for 109,076 participants, yielding 5,544 IgG positive results and adjusted (for test performance), re-weighted (for sampling) prevalence of 6.0% (95% CI: 5.8, 6.1). Highest prevalence was in London (13.0% [12.3, 13.6]), among people of Black or Asian (mainly South Asian) ethnicity (17.3% [15.8, 19.1] and 11.9% [11.0, 12.8] respectively) and those aged 18-24 years (7.9% [7.3, 8.5]). Care home workers with client-facing roles had adjusted odds ratio of 3.1 (2.5, 3.8) compared with non-essential workers. One third (32.2%, [31.0-33.4]) of antibody positive individuals reported no symptoms. Among symptomatic cases, the majority (78.8%) reported symptoms during the peak of the epidemic in England in March (31.3%) and April (47.5%) 2020. We estimate that 3.36 million (3.21, 3.51) people have been infected with SARS-CoV-2 in England to end June 2020, with an overall infection fatality ratio of 0.90% (0.86, 0.94). Conclusion The pandemic of SARS-CoV-2 infection in England disproportionately affected ethnic minority groups and health and care home workers. The higher risk of infection in these groups may explain, at least in part, their increased risk of hospitalisation and mortality from COVID-19.
- Published
- 2020
9. Report 30: The COVID-19 epidemic trends and control measures in mainland China
- Author
-
Fu, H, Xi, X, Wang, H, Boonyasiri, A, Wang, Y, Hinsley, W, Fraser, K, McCabe, R, Olivera Mesa, D, Skarp, J, Ledda, A, Dewe, T, Dighe, A, Winskill, P, Van Elsland, S, Ainslie, K, Baguelin, M, Bhatt, S, Boyd, O, Brazeau, N, Cattarino, L, Charles, G, Coupland, H, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Donnelly, C, Dorigatti, I, Green, W, Hamlet, A, Hauck, K, Haw, D, Jeffrey, B, Laydon, D, Lees, J, Mellan, T, Mishra, S, Nedjati Gilani, G, Nouvellet, P, Okell, L, Parag, K, Ragonnet-Cronin, M, Riley, S, Schmit, N, Thompson, H, Unwin, H, Verity, R, Vollmer, M, Volz, E, Walker, P, Walters, C, Watson, O, Whittaker, C, Whittles, L, Imai, N, Bhatia, S, Ferguson, N, and Medical Research Council (MRC)
- Subjects
Coronavirus ,China ,COVID19 ,COVID-19 - Published
- 2020
10. Potential impact of the COVID-19 pandemic on HIV, TB and malaria in low- and middle-income countries: a modelling study
- Author
-
Hogan, A, Jewell, B, Sherrard-Smith, E, Watson, O, Whittaker, C, Hamlet, A, Smith, J, Winskill, P, Verity, R, Baguelin, M, Lees, J, Whittles, L, Ainslie, K, Bhatt, S, Boonyasiri, A, Brazeau, N, Cattarino, L, Cooper, L, Coupland, H, Cuomo-Dannenburg, G, Dighe, A, Djaafara, A, Donnelly, C, Eaton, J, Van Elsland, S, Fitzjohn, R, Fu, H, Gaythorpe, K, Green, W, Haw, D, Hayes, S, Hinsley, W, Imai, N, Laydon, D, Mangal, T, Mellan, T, Mishra, S, Parag, K, Thompson, H, Unwin, H, Vollmer, M, Walters, C, Wang, H, Ferguson, N, Okell, L, Churcher, T, Arinaminpathy, N, Ghani, A, Walker, P, Hallett, T, Medical Research Council (MRC), Bill & Melinda Gates Foundation, Wellcome Trust, Imperial College Healthcare NHS Trust- BRC Funding, The Academy of Medical Sciences, National Institute for Health Research, Imperial College LOndon, Medical Research Council, and The Royal Society
- Subjects
Pneumonia, Viral ,Humans ,Tuberculosis ,HIV Infections ,Models, Theoretical ,Coronavirus Infections ,Developing Countries ,Pandemics ,Health Services Accessibility ,Malaria ,0605 Microbiology ,1117 Public Health and Health Services - Abstract
Background: COVID-19 has the potential to cause substantial disruptions to health services, including by cases overburdening the health system or response measures limiting usual programmatic activities. We aimed to quantify the extent to which disruptions in services for human immunodeficiency virus (HIV), tuberculosis (TB) and malaria in low- and middle-income countries with high burdens of those disease could lead to additional loss of life. Methods: We constructed plausible scenarios for the disruptions that could be incurred during the COVID-19 pandemic and used established transmission models for each disease to estimate the additional impact on health that could be caused in selected settings. Findings: In high burden settings, HIV-, TB- and malaria-related deaths over five years may increase by up to 10%, 20% and 36%, respectively, compared to if there were no COVID-19 pandemic. We estimate the greatest impact on HIV to be from interruption to antiretroviral therapy, which may occur during a period of high health system demand. For TB, we estimate the greatest impact is from reductions in timely diagnosis and treatment of new cases, which may result from any prolonged period of COVID-19 suppression interventions. We estimate that the greatest impact on malaria burden could come from interruption of planned net campaigns. These disruptions could lead to loss of life-years over five years that is of the same order of magnitude as the direct impact from COVID-19 in places with a high burden of malaria and large HIV/TB epidemics. Interpretation: Maintaining the most critical prevention activities and healthcare services for HIV, TB and malaria could significantly reduce the overall impact of the COVID-19 pandemic. Funding: Bill & Melinda Gates Foundation, The Wellcome Trust, DFID, MRC
- Published
- 2020
11. Estimating the number of undetected COVID-19 cases among travellers from mainland China
- Author
-
Bhatia, S, Imai, N, Cuomo-Dannenburg, G, Baguelin, M, Boonyasiri, A, Cori, A, Cucunuba Perez, Z, Dorigatti, I, Fitzjohn, R, Fu, H, Gaythorpe, K, Ghani, A, Hamlet, A, Hinsley, W, Laydon, D, Nedjati Gilani, G, Okell, L, Riley, S, Thompson, H, Van Elsland, S, Volz, E, Wang, H, Wang, Y, Whittaker, C, Xi, X, Donnelly, CA, Ferguson, NM, and Medical Research Council (MRC)
- Abstract
Background: Since the start of the COVID-19 epidemic in late 2019, there have been more than 152 affected regions and countries with over 110,000 confirmed cases outside mainland China. Methods: We analysed COVID-19 cases among travellers from mainland China to different regions and countries, comparing the region- and country-specific rates of detected and confirmed cases per flight volume to estimate the relative sensitivity of surveillance in different regions and countries. Results: Although travel restrictions from Wuhan City and other cities across China may have reduced the absolute number of travellers to and from China, we estimated that more than two thirds (70%, 95% CI: 54% - 80%, compared to Singapore; 75%, 95% CI: 66% - 82%, compared to multiple countries) of cases exported from mainland China have remained undetected. Conclusions: These undetected cases potentially resulted in multiple chains of human-to-human transmission outside mainland China.
- Published
- 2020
12. Report 23: State-level tracking of COVID-19 in the United States
- Author
-
Unwin, H, Mishra, S, Bradley, VC, Gandy, A, Vollmer, M, Mellan, T, Coupland, H, Ainslie, K, Whittaker, C, Ish-Horowicz, J, Filippi, S, Xi, X, Monod, M, Ratmann, O, Hutchinson, M, Valka, F, Zhu, H, Hawryluk, I, Milton, P, Baguelin, M, Boonyasiri, A, Brazeau, N, Cattarino, L, Charles, G, Cooper, L, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Djaafara, A, Dorigatti, I, Eales, O, Eaton, J, Van Elsland, S, Fitzjohn, R, Gaythorpe, K, Green, W, Hallett, T, Hinsley, W, Imai, N, Jeffrey, B, Knock, E, Laydon, D, Lees, J, Nedjati Gilani, G, Nouvellet, P, Okell, L, Ower, A, Parag, K, Siveroni, I, Thompson, H, Verity, R, Walker, P, Walters, C, Wang, Y, Watson, O, Whittles, L, Ghani, A, Ferguson, N, Riley, S, Donnelly, C, Bhatt, S, Flaxman, S, and Medical Research Council (MRC)
- Subjects
Coronavirus ,COVID19 ,COVID-19 ,United States - Abstract
our estimates show that the percentage of individuals that have been infected is 4.1% [3.7%-4.5%], with wide variation between states. For all states, even for the worst affected states, we estimate that less than a quarter of the population has been infected; in New York, for example, we estimate that 16.6% [12.8%-21.6%] of individuals have been infected to date. Our attack rates for New York are in line with those from recent serological studies [1] broadly supporting our choice of infection fatality rate. There is variation in the initial reproduction number, which is likely due to a range of factors; we find a strong association between the initial reproduction number with both population density (measured at the state level) and the chronological date when 10 cumulative deaths occurred (a crude estimate of the date of locally sustained transmission). Our estimates suggest that the epidemic is not under control in much of the US: as of 17 May 2020 the reproduction number is above the critical threshold (1.0) in 24 [95% CI: 20-30] states. Higher reproduction numbers are geographically clustered in the South and Midwest, where epidemics are still developing, while we estimate lower reproduction numbers in states that have already suffered high COVID-19 mortality (such as the Northeast). These estimates suggest that caution must be taken in loosening current restrictions if effective additional measures are not put in place. We predict that increased mobility following relaxation of social distancing will lead to resurgence of transmission, keeping all else constant. We predict that deaths over the next two-month period could exceed current cumulative deaths by greater than two-fold, if the relationship between mobility and transmission remains unchanged. Our results suggest that factors modulating transmission such as rapid testing, contact tracing and behavioural precautions are crucial to offset the rise of transmission associated with loosening of social distancing. Overall, we show that while all US states have substantially reduced their reproduction numbers, there is little evidence that any states are approaching herd immunity and thus the epidemic is close to over in any state.
- Published
- 2020
- Full Text
- View/download PDF
13. Report 22: Equity in response to the COVID-19 pandemic: an assessment of the direct and indirect impacts on disadvantaged and vulnerable populations in low- and lower middle-income countries
- Author
-
Winskill, P, Whittaker, C, Walker, P, Watson, O, Laydon, D, Imai, N, Cuomo-Dannenburg, G, Ainslie, K, Baguelin, M, Bhatt, S, Boonyasiri, A, Cattarino, L, Ciavarella, C, Cooper, L, Coupland, H, Cucunuba Perez, Z, Van Elsland, S, Fitzjohn, R, Flaxman, S, Gaythorpe, K, Green, W, Hallett, T, Hamlet, A, Hinsley, W, Knock, E, Lees, J, Mellan, T, Mishra, S, Nedjati Gilani, G, Nouvellet, P, Okell, L, Parag, K, Thompson, H, Unwin, H, Wang, Y, Whittles, L, Xi, X, Ferguson, N, Donnelly, C, Ghani, A, and Medical Research Council (MRC)
- Subjects
Coronavirus ,COVID19 ,COVID-19 ,Equity - Abstract
The impact of the COVID-19 pandemic in low-income settings is likely to be more severe due to limited healthcare capacity. Within these settings, however, there exists unfair or avoidable differences in health among different groups in society – health inequities – that mean that some groups are particularly at risk from the negative direct and indirect consequences of COVID-19. The structural determinants of these are often reflected in differences by income strata, with the poorest populations having limited access to preventative measures such as handwashing. Their more fragile income status will also mean that they are likely to be employed in occupations that are not amenable to social-distancing measures, thereby further reducing their ability to protect themselves from infection. Furthermore, these populations may also lack access to timely healthcare on becoming ill. We explore these relationships by using large-scale household surveys to quantify the differences in handwashing access, occupation and hospital access with respect to wealth status in low-income settings. We use a COVID-19 transmission model to demonstrate the impact of these differences. Our results demonstrate clear trends that the probability of death from COVID-19 increases with increasing poverty. On average, we estimate a 32.0% (2.5th-97.5th centile 8.0%-72.5%) increase in the probability of death in the poorest quintile compared to the wealthiest quintile from these three factors alone. We further explore how risk mediators and the indirect impacts of COVID-19 may also hit these same disadvantaged and vulnerable the hardest. We find that larger, inter-generational households that may hamper efforts to protect the elderly if social distancing are associated with lower-income countries and, within LMICs, lower wealth status. Poorer populations are also more susceptible to food security issues - with these populations having the highest levels under-nourishment whilst also being most dependent on their own food production. We show that timing of the COVID-19 epidemic in low-resource settings has the potential to interrupt planting and harvesting seasons for staple crops, thereby accentuating this vulnerability. These enhanced risks and key vulnerabilities – alongside the broader concerns surrounding displaced or conflict-affected populations - demonstrate the challenges that the most marginalised populations face during the ongoing COVID-19 pandemic.
- Published
- 2020
- Full Text
- View/download PDF
14. Report 21: Estimating COVID-19 cases and reproduction number in Brazil
- Author
-
Mellan, T, Hoeltgebaum, H, Mishra, S, Whittaker, C, Schnekenberg, R, Gandy, A, Unwin, H, Vollmer, M, Coupland, H, Hawryluk, I, Rodrigues Faria, N, Vesga, J, Zhu, H, Hutchinson, M, Ratmann, O, Monod, M, Ainslie, K, Baguelin, M, Bhatia, S, Boonyasiri, A, Brazeau, N, Charles, G, Cooper, L, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Dighe, A, Djaafara, A, Eaton, J, Van Elsland, S, Fitzjohn, R, Fraser, K, Gaythorpe, K, Green, W, Hayes, S, Imai, N, Jeffrey, B, Knock, E, Laydon, D, Lees, J, Mangal, T, Mousa, A, Nedjati Gilani, G, Nouvellet, P, Olivera Mesa, D, Parag, K, Pickles, M, Thompson, H, Verity, R, Walters, C, Wang, H, Wang, Y, Watson, O, Whittles, L, Xi, X, Okell, L, Dorigatti, I, Walker, P, Ghani, A, Riley, S, Ferguson, N, Donnelly, C, Flaxman, S, Bhatt, S, and Medical Research Council (MRC)
- Subjects
Coronavirus ,0303 health sciences ,03 medical and health sciences ,0302 clinical medicine ,COVID19 ,COVID-19 ,030212 general & internal medicine ,Brazil ,3. Good health ,030304 developmental biology - Abstract
Brazil is an epicentre for COVID-19 in Latin America. In this report we describe the Brazilian epidemic using three epidemiological measures: the number of infections, the number of deaths and the reproduction number. Our modelling framework requires sufficient death data to estimate trends, and we therefore limit our analysis to 16 states that have experienced a total of more than fifty deaths. The distribution of deaths among states is highly heterogeneous, with 5 states—São Paulo, Rio de Janeiro, Ceará, Pernambuco and Amazonas—accounting for 81% of deaths reported to date. In these states, we estimate that the percentage of people that have been infected with SARS-CoV-2 ranges from 3.3% (95% CI: 2.8%-3.7%) in São Paulo to 10.6% (95% CI: 8.8%-12.1%) in Amazonas. The reproduction number (a measure of transmission intensity) at the start of the epidemic meant that an infected individual would infect three or four others on average. Following non-pharmaceutical interventions such as school closures and decreases in population mobility, we show that the reproduction number has dropped substantially in each state. However, for all 16 states we study, we estimate with high confidence that the reproduction number remains above 1. A reproduction number above 1 means that the epidemic is not yet controlled and will continue to grow. These trends are in stark contrast to other major COVID19 epidemics in Europe and Asia where enforced lockdowns have successfully driven the reproduction number below 1. While the Brazilian epidemic is still relatively nascent on a national scale, our results suggest that further action is needed to limit spread and prevent health system overload.
- Published
- 2020
15. Report 20: A sub-national analysis of the rate of transmission of Covid-19 in Italy
- Author
-
Vollmer, M, Mishra, S, Unwin, H, Gandy, A, Melan, T, Bradley, V, Zhu, H, Coupland, H, Hawryluk, I, Hutchinson, M, Ratmann, O, Monod, M, Walker, P, Whittaker, C, Cattarino, L, Ciavarella, C, Cilloni, L, Ainslie, K, Baguelin, M, Bhatia, S, Boonyasiri, A, Brazeau, N, Charles, G, Cooper, L, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Dighe, A, Djaafara, A, Eaton, J, Van Elsland, S, Fitzjohn, R, Fraser, K, Gaythorpe, K, Green, W, Hayes, S, Imai, N, Jeffrey, B, Knock, E, Laydon, D, Lees, J, Mangal, T, Mousa, A, Nedjati Gilani, G, Nouvellet, P, Olivera Mesa, D, Parag, K, Pickles, M, Thompson, H, Verity, R, Walters, C, Wang, H, Wang, Y, Watson, O, Whittles, L, Xi, X, Ghani, A, Riley, S, Okell, L, Donnelly, C, Ferguson, N, Dorigatti, I, Flaxman, S, Bhatt, S, and Medical Research Council (MRC)
- Subjects
Coronavirus ,Italy ,COVID19 ,Lockdown ,COVID-19 ,Transmission - Abstract
Italy was the first European country to experience sustained local transmission of COVID-19. As of 1st May 2020, the Italian health authorities reported 28; 238 deaths nationally. To control the epidemic, the Italian government implemented a suite of non-pharmaceutical interventions (NPIs), including school and university closures, social distancing and full lockdown involving banning of public gatherings and non essential movement. In this report, we model the effect of NPIs on transmission using data on average mobility. We estimate that the average reproduction number (a measure of transmission intensity) is currently below one for all Italian regions, and significantly so for the majority of the regions. Despite the large number of deaths, the proportion of population that has been infected by SARS-CoV-2 (the attack rate) is far from the herd immunity threshold in all Italian regions, with the highest attack rate observed in Lombardy (13.18% [10.66%-16.70%]). Italy is set to relax the currently implemented NPIs from 4th May 2020. Given the control achieved by NPIs, we consider three scenarios for the next 8 weeks: a scenario in which mobility remains the same as during the lockdown, a scenario in which mobility returns to pre-lockdown levels by 20%, and a scenario in which mobility returns to pre-lockdown levels by 40%. The scenarios explored assume that mobility is scaled evenly across all dimensions, that behaviour stays the same as before NPIs were implemented, that no pharmaceutical interventions are introduced, and it does not include transmission reduction from contact tracing, testing and the isolation of confirmed or suspected cases. We find that, in the absence of additional interventions, even a 20% return to pre-lockdown mobility could lead to a resurgence in the number of deaths far greater than experienced in the current wave in several regions. Future increases in the number of deaths will lag behind the increase in transmission intensity and so a second wave will not be immediately apparent from just monitoring of the daily number of deaths. Our results suggest that SARS-CoV-2 transmission as well as mobility should be closely monitored in the next weeks and months. To compensate for the increase in mobility that will occur due to the relaxation of the currently implemented NPIs, enhanced community surveillance including swab testing, contact tracing and the early isolation of infections are of paramount importance to reduce the risk of resurgence in transmission.
- Published
- 2020
- Full Text
- View/download PDF
16. Report 18: The potential public health impact of COVID-19 on malaria in Africa
- Author
-
Sherrard-Smith, E, Hogan, A, Hamlet, A, Watson, OJ, Whittaker, C, Winskill, P, Verity, R, Lambert, B, Cairns, M, Okell, L, Slater, H, Ghani, A, Walker, P, Churcher, T, Imperial College COVID19 response team, and Medical Research Council (MRC)
- Subjects
parasitic diseases - Abstract
The COVID-19 pandemic is likely to severely interrupt health systems in Sub-Saharan Africa (SSA) over the coming weeks and months. Approximately 90% of malaria deaths occur in this region of the world, with an estimated 380,000 deaths from malaria in 2018. Much of the gain made in malaria control over the last decade has been due to the distribution of long-lasting insecticide treated nets (LLINs). Many SSA countries planned to distribute these in 2020. We used COVID-19 and malaria transmission models to understand the likely impact that disruption to these distributions, alongside other core health services, could have on the malaria burden. Results indicate that if all malaria-control activities are highly disrupted then the malaria burden in 2020 could more than double that in the previous year, resulting in large malaria epidemics across the region. These will depend on the course of the COVID-19 epidemic and how it interrupts local health system. Our results also demonstrate that it is essential to prioritise the LLIN distributions either before or as soon as possible into local COVID-19 epidemics to mitigate this risk. Additional planning to ensure other malaria prevention activities are continued where possible, alongside planning to ensure basic access to antimalarial treatment, will further minimise the risk of substantial additional malaria mortality.
- Published
- 2020
- Full Text
- View/download PDF
17. Report 19: The potential impact of the COVID-19 epidemic on HIV, TB and malaria in low- and middle-income countries
- Author
-
Hogan, A, Jewell, B, Sherrard-Smith, E, Vesga, J, Watson, O, Whittaker, C, Hamlet, A, Smith, J, Ainslie, K, Baguelin, M, Bhatt, S, Boonyasiri, A, Brazeau, N, Cattarino, L, Charles, G, Cooper, L, Coupland, H, Cuomo-Dannenburg, G, Dighe, A, Djaafara, A, Donnelly, C, Dorigatti, I, Eaton, J, Van Elsland, S, Fitzjohn, R, Fu, H, Gaythorpe, K, Green, W, Haw, D, Hayes, S, Hinsley, W, Imai, N, Knock, E, Laydon, D, Lees, J, Mangal, T, Mellan, T, Mishra, S, Nedjati Gilani, G, Nouvellet, P, Okell, L, Ower, A, Parag, K, Pickles, M, Stopard, I, Thompson, H, Unwin, H, Verity, R, Vollmer, M, Walters, C, Wang, H, Wang, Y, Whittles, L, Winskill, P, Xi, X, Ferguson, N, Churcher, T, Arinaminpathy, N, Ghani, A, Walker, P, Hallett, T, and Medical Research Council (MRC)
- Abstract
COVID-19 has the potential to cause disruptions to health services in different ways; through the health system becoming overwhelmed with COVID-19 patients, through the intervention used to slow transmission of COVID-19 inhibiting access to preventative interventions and services, and through supplies of medicine being interrupted. We aim to quantify the extent to which such disruptions in services for HIV, TB and malaria in high burden low- and middle-income countries could lead to additional loss of life. In high burden settings, HIV, TB and malaria related deaths over 5 years may be increased by up to 10%, 20% and 36%, respectively, compared to if there were no COVID-19 epidemic. We estimate the greatest impact on HIV to be from interruption to ART, which may occur during a period of high or extremely high health system demand; for TB, we estimate the greatest impact is from reductions in timely diagnosis and treatment of new cases, which may result from a long period of COVID-19 suppression interventions; for malaria, we estimate that the greatest impact could come from reduced prevention activities including interruption of planned net campaigns, through all phases of the COVID-19 epidemic. In high burden settings, the impact of each type of disruption could be significant and lead to a loss of life-years over five years that is of the same order of magnitude as the direct impact from COVID-19 in places with a high burden of malaria and large HIV/TB epidemics. Maintaining the most critical prevention activities and healthcare services for HIV, TB and malaria could significantly reduce the overall impact of the COVID-19 epidemic.
- Published
- 2020
- Full Text
- View/download PDF
18. Report 16: Role of testing in COVID-19 control
- Author
-
Grassly, N, Pons Salort, M, Parker, E, White, P, Ainslie, K, Baguelin, M, Bhatt, S, Boonyasiri, A, Boyd, O, Brazeau, N, Cattarino, L, Ciavarella, C, Cooper, L, Coupland, H, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Dighe, A, Djaafara, A, Donnelly, C, Dorigatti, I, Van Elsland, S, Ferreira Do Nascimento, F, Fitzjohn, R, Fu, H, Gaythorpe, K, Geidelberg, L, Green, W, Hallett, T, Hamlet, A, Hayes, S, Hinsley, W, Imai, N, Jorgensen, D, Knock, E, Laydon, D, Lees, J, Mangal, T, Mellan, T, Mishra, S, Nedjati Gilani, G, Nouvellet, P, Okell, L, Ower, A, Parag, K, Pickles, M, Ragonnet-Cronin, M, Stopard, I, Thompson, H, Unwin, H, Verity, R, Vollmer, M, Volz, E, Walker, P, Walters, C, Wang, H, Wang, Y, Watson, O, Whittaker, C, Whittles, L, Winskill, P, Xi, X, Ferguson, N, and Medical Research Council (MRC)
- Subjects
Coronavirus ,COVID19 ,Testing ,COVID-19 - Abstract
The World Health Organization has called for increased molecular testing in response to the COVID-19 pandemic, but different countries have taken very different approaches. We used a simple mathematical model to investigate the potential effectiveness of alternative testing strategies for COVID-19 control. Weekly screening of healthcare workers (HCWs) and other at-risk groups using PCR or point-of-care tests for infection irrespective of symptoms is estimated to reduce their contribution to transmission by 25-33%, on top of reductions achieved by self-isolation following symptoms. Widespread PCR testing in the general population is unlikely to limit transmission more than contact-tracing and quarantine based on symptoms alone, but could allow earlier release of contacts from quarantine. Immunity passports based on tests for antibody or infection could support return to work but face significant technical, legal and ethical challenges. Testing is essential for pandemic surveillance but its direct contribution to the prevention of transmission is likely to be limited to patients, HCWs and other high-risk groups.
- Published
- 2020
19. Report 13: Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries
- Author
-
Flaxman, S, Mishra, S, Gandy, A, Unwin, H, Coupland, H, Mellan, T, Zhu, H, Berah, T, Eaton, J, Perez Guzman, P, Schmit, N, Cilloni, L, Ainslie, K, Baguelin, M, Blake, I, Boonyasiri, A, Boyd, O, Cattarino, L, Ciavarella, C, Cooper, L, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Dighe, A, Djaafara, A, Dorigatti, I, Van Elsland, S, Fitzjohn, R, Fu, H, Gaythorpe, K, Geidelberg, L, Grassly, N, Green, W, Hallett, T, Hamlet, A, Hinsley, W, Jeffrey, B, Jorgensen, D, Knock, E, Laydon, D, Nedjati Gilani, G, Nouvellet, P, Parag, K, Siveroni, I, Thompson, H, Verity, R, Volz, E, Walters, C, Wang, H, Wang, Y, Watson, O, Winskill, P, Xi, X, Whittaker, C, Walker, P, Ghani, A, Donnelly, C, Riley, S, Okell, L, Vollmer, M, Ferguson, N, Bhatt, S, Medical Research Council (MRC), and The Royal Society
- Subjects
Europe ,COVID19 ,Non-pharmaceutical Interventions ,Pneumonia, Viral ,Coronavirus Infections ,CoronaVirus - Abstract
Following the emergence of a novel coronavirus (SARS-CoV-2) and its spread outside of China, Europe is now experiencing large epidemics. In response, many European countries have implemented unprecedented non-pharmaceutical interventions including case isolation, the closure of schools and universities, banning of mass gatherings and/or public events, and most recently, widescale social distancing including local and national lockdowns. In this report, we use a semi-mechanistic Bayesian hierarchical model to attempt to infer the impact of these interventions across 11 European countries. Our methods assume that changes in the reproductive number – a measure of transmission - are an immediate response to these interventions being implemented rather than broader gradual changes in behaviour. Our model estimates these changes by calculating backwards from the deaths observed over time to estimate transmission that occurred several weeks prior, allowing for the time lag between infection and death. One of the key assumptions of the model is that each intervention has the same effect on the reproduction number across countries and over time. This allows us to leverage a greater amount of data across Europe to estimate these effects. It also means that our results are driven strongly by the data from countries with more advanced epidemics, and earlier interventions, such as Italy and Spain. We find that the slowing growth in daily reported deaths in Italy is consistent with a significant impact of interventions implemented several weeks earlier. In Italy, we estimate that the effective reproduction number, Rt, dropped to close to 1 around the time of lockdown (11th March), although with a high level of uncertainty. Overall, we estimate that countries have managed to reduce their reproduction number. Our estimates have wide credible intervals and contain 1 for countries that have implemented all interventions considered in our analysis. This means that the reproduction number may be above or below this value. With current interventions remaining in place to at least the end of March, we estimate that interventions across all 11 countries will have averted 59,000 deaths up to 31 March [95% credible interval 21,000-120,000]. Many more deaths will be averted through ensuring that interventions remain in place until transmission drops to low levels. We estimate that, across all 11 countries between 7 and 43 million individuals have been infected with SARS-CoV-2 up to 28th March, representing between 1.88% and 11.43% of the population. The proportion of the population infected to date – the attack rate - is estimated to be highest in Spain followed by Italy and lowest in Germany and Norway, reflecting the relative stages of the epidemics. Given the lag of 2-3 weeks between when transmission changes occur and when their impact can be observed in trends in mortality, for most of the countries considered here it remains too early to be certain that recent interventions have been effective. If interventions in countries at earlier stages of their epidemic, such as Germany or the UK, are more or less effective than they were in the countries with advanced epidemics, on which our estimates are largely based, or if interventions have improved or worsened over time, then our estimates of the reproduction number and deaths averted would change accordingly. It is therefore critical that the current interventions remain in place and trends in cases and deaths are closely monitored in the coming days and weeks to provide reassurance that transmission of SARS-Cov-2 is slowing.
- Published
- 2020
20. Report 12: The global impact of COVID-19 and strategies for mitigation and suppression
- Author
-
Walker, P, Whittaker, C, Watson, O, Baguelin, M, Ainslie, K, Bhatia, S, Bhatt, S, Boonyasiri, A, Boyd, O, Cattarino, L, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Dighe, A, Donnelly, C, Dorigatti, I, Van Elsland, S, Fitzjohn, R, Flaxman, S, Fu, H, Gaythorpe, K, Geidelberg, L, Grassly, N, Green, W, Hamlet, A, Hauck, K, Haw, D, Hayes, S, Hinsley, W, Imai, N, Jorgensen, D, Knock, E, Laydon, D, Mishra, S, Nedjati Gilani, G, Okell, L, Riley, S, Thompson, H, Unwin, H, Verity, R, Vollmer, M, Walters, C, Wang, H, Wang, Y, Winskill, P, Xi, X, Ferguson, N, Ghani, A, Medical Research Council (MRC), and The Royal Society
- Subjects
Coronavirus ,COVID19 ,Global Burden - Abstract
The world faces a severe and acute public health emergency due to the ongoing COVID-19 global pandemic. How individual countries respond in the coming weeks will be critical in influencing the trajectory of national epidemics. Here we combine data on age-specific contact patterns and COVID-19 severity to project the health impact of the pandemic in 202 countries. We compare predicted mortality impacts in the absence of interventions or spontaneous social distancing with what might be achieved with policies aimed at mitigating or suppressing transmission. Our estimates of mortality and healthcare demand are based on data from China and high-income countries; differences in underlying health conditions and healthcare system capacity will likely result in different patterns in low income settings. We estimate that in the absence of interventions, COVID-19 would have resulted in 7.0 billion infections and 40 million deaths globally this year. Mitigation strategies focussing on shielding the elderly (60% reduction in social contacts) and slowing but not interrupting transmission (40% reduction in social contacts for wider population) could reduce this burden by half, saving 20 million lives, but we predict that even in this scenario, health systems in all countries will be quickly overwhelmed. This effect is likely to be most severe in lower income settings where capacity is lowest: our mitigated scenarios lead to peak demand for critical care beds in a typical low-income setting outstripping supply by a factor of 25, in contrast to a typical high-income setting where this factor is 7. As a result, we anticipate that the true burden in low income settings pursuing mitigation strategies could be substantially higher than reflected in these estimates. Our analysis therefore suggests that healthcare demand can only be kept within manageable levels through the rapid adoption of public health measures (including testing and isolation of cases and wider social distancing measures) to suppress transmission, similar to those being adopted in many countries at the current time. If a suppression strategy is implemented early (at 0.2 deaths per 100,000 population per week) and sustained, then 38.7 million lives could be saved whilst if it is initiated when death numbers are higher (1.6 deaths per 100,000 population per week) then 30.7 million lives could be saved. Delays in implementing strategies to suppress transmission will lead to worse outcomes and fewer lives saved. We do not consider the wider social and economic costs of suppression, which will be high and may be disproportionately so in lower income settings. Moreover, suppression strategies will need to be maintained in some manner until vaccines or effective treatments become available to avoid the risk of later epidemics. Our analysis highlights the challenging decisions faced by all governments in the coming weeks and months, but demonstrates the extent to which rapid, decisive and collective action now could save millions of lives.
- Published
- 2020
- Full Text
- View/download PDF
21. Report 11: Evidence of initial success for China exiting COVID-19 social distancing policy after achieving containment
- Author
-
Ainslie, K, Walters, C, Fu, H, Bhatia, S, Wang, H, Baguelin, M, Bhatt, S, Boonyasiri, A, Boyd, O, Cattarino, L, Ciavarella, C, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Dighe, A, Dorigatti, I, Van Elsland, S, Fitzjohn, R, Gaythorpe, K, Geidelberg, L, Ghani, A, Green, W, Hamlet, A, Hauck, K, Hinsley, W, Imai, N, Jorgensen, D, Knock, E, Laydon, D, Nedjati Gilani, G, Okell, L, Siveroni, I, Thompson, H, Unwin, H, Verity, R, Vollmer, M, Walker, P, Wang, Y, Watson, O, Whittaker, C, Winskill, P, Xi, X, Donnelly, C, Ferguson, N, Riley, S, Medical Research Council (MRC), and The Royal Society
- Subjects
Coronavirus ,COVID19 ,Containment ,Social Distancing - Abstract
The COVID-19 epidemic was declared a Global Pandemic by WHO on 11 March 2020. As of 20 March 2020, over 254,000 cases and 10,000 deaths had been reported worldwide. The outbreak began in the Chinese city of Wuhan in December 2019. In response to the fast-growing epidemic, China imposed strict social distancing in Wuhan on 23 January 2020 followed closely by similar measures in other provinces. At the peak of the outbreak in China (early February), there were between 2,000 and 4,000 new confirmed cases per day. For the first time since the outbreak began there have been no new confirmed cases caused by local transmission in China reported for five consecutive days up to 23 March 2020. This is an indication that the social distancing measures enacted in China have led to control of COVID-19 in China. These interventions have also impacted economic productivity in China, and the ability of the Chinese economy to resume without restarting the epidemic is not yet clear. Here, we estimate transmissibility from reported cases and compare those estimates with daily data on within-city movement, as a proxy for economic activity. Initially, within-city movement and transmission were very strongly correlated in the 5 provinces most affected by the epidemic and Beijing. However, that correlation is no longer apparent even though within-city movement has started to increase. A similar analysis for Hong Kong shows that intermediate levels of local activity can be maintained while avoiding a large outbreak. These results do not preclude future epidemics in China, nor do they allow us to estimate the maximum proportion of previous within-city activity that will be recovered in the medium term. However, they do suggest that after very intense social distancing which resulted in containment, China has successfully exited their stringent social distancing policy to some degree. Globally, China is at a more advanced stage of the pandemic. Policies implemented to reduce the spread of COVID-19 in China and the exiting strategies that followed can inform decision making processes for countries once containment is achieved.
- Published
- 2020
- Full Text
- View/download PDF
22. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand
- Author
-
Ferguson, N, Laydon, D, Nedjati Gilani, G, Imai, N, Ainslie, K, Baguelin, M, Bhatia, S, Boonyasiri, A, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Dighe, A, Dorigatti, I, Fu, H, Gaythorpe, K, Green, W, Hamlet, A, Hinsley, W, Okell, L, Van Elsland, S, Thompson, H, Verity, R, Volz, E, Wang, H, Wang, Y, Walker, P, Walters, C, Winskill, P, Whittaker, C, Donnelly, C, Riley, S, Ghani, A, Medical Research Council (MRC), and The Royal Society
- Subjects
Coronavirus ,COVID19 ,Non-pharmaceutical interventions ,healthcare demand ,Mortality - Abstract
The global impact of COVID-19 has been profound, and the public health threat it represents is the most serious seen in a respiratory virus since the 1918 H1N1 influenza pandemic. Here we present the results of epidemiological modelling which has informed policymaking in the UK and other countries in recent weeks. In the absence of a COVID-19 vaccine, we assess the potential role of a number of public health measures – so-called non-pharmaceutical interventions (NPIs) – aimed at reducing contact rates in the population and thereby reducing transmission of the virus. In the results presented here, we apply a previously published microsimulation model to two countries: the UK (Great Britain specifically) and the US. We conclude that the effectiveness of any one intervention in isolation is likely to be limited, requiring multiple interventions to be combined to have a substantial impact on transmission. Two fundamental strategies are possible: (a) mitigation, which focuses on slowing but not necessarily stopping epidemic spread – reducing peak healthcare demand while protecting those most at risk of severe disease from infection, and (b) suppression, which aims to reverse epidemic growth, reducing case numbers to low levels and maintaining that situation indefinitely. Each policy has major challenges. We find that that optimal mitigation policies (combining home isolation of suspect cases, home quarantine of those living in the same household as suspect cases, and social distancing of the elderly and others at most risk of severe disease) might reduce peak healthcare demand by 2/3 and deaths by half. However, the resulting mitigated epidemic would still likely result in hundreds of thousands of deaths and health systems (most notably intensive care units) being overwhelmed many times over. For countries able to achieve it, this leaves suppression as the preferred policy option. We show that in the UK and US context, suppression will minimally require a combination of social distancing of the entire population, home isolation of cases and household quarantine of their family members. This may need to be supplemented by school and university closures, though it should be recognised that such closures may have negative impacts on health systems due to increased absenteeism. The major challenge of suppression is that this type of intensive intervention package – or something equivalently effective at reducing transmission – will need to be maintained until a vaccine becomes available (potentially 18 months or more) – given that we predict that transmission will quickly rebound if interventions are relaxed. We show that intermittent social distancing – triggered by trends in disease surveillance – may allow interventions to be relaxed temporarily in relative short time windows, but measures will need to be reintroduced if or when case numbers rebound. Last, while experience in China and now South Korea show that suppression is possible in the short term, it remains to be seen whether it is possible long-term, and whether the social and economic costs of the interventions adopted thus far can be reduced.
- Published
- 2020
- Full Text
- View/download PDF
23. Report 8: Symptom progression of COVID-19
- Author
-
Gaythorpe, K, Imai, N, Cuomo-Dannenburg, G, Baguelin, M, Bhatia, S, Boonyasiri, A, Cori, A, Cucunuba Perez, Z, Dighe, A, Dorigatti, I, Fitzjohn, R, Fu, H, Green, W, Griffin, J, Hamlet, A, Hinsley, W, Hong, N, Kwun, M, Laydon, D, Nedjati Gilani, G, Okell, L, Riley, S, Thompson, H, Van Elsland, S, Verity, R, Volz, E, Walker, P, Wang, H, Wang, Y, Walters, C, Whittaker, C, Winskill, P, Xi, X, Donnelly, C, Ghani, A, Ferguson, N, Medical Research Council (MRC), and The Royal Society
- Subjects
Coronavirus ,COVID19 ,Symptom - Abstract
The COVID-19 epidemic was declared a Public Health Emergency of International Concern (PHEIC) by WHO on 30th January 2020 [1]. As of 8 March 2020, over 107,000 cases had been reported. Here, we use published and preprint studies of clinical characteristics of cases in mainland China as well as case studies of individuals from Hong Kong, Japan, Singapore and South Korea to examine the proportional occurrence of symptoms and the progression of symptoms through time. We find that in mainland China, where specific symptoms or disease presentation are reported, pneumonia is the most frequently mentioned, see figure 1. We found a more varied spectrum of severity in cases outside mainland China. In Hong Kong, Japan, Singapore and South Korea, fever was the most frequently reported symptom. In this latter group, presentation with pneumonia is not reported as frequently although it is more common in individuals over 60 years old. The average time from reported onset of first symptoms to the occurrence of specific symptoms or disease presentation, such as pneumonia or the use of mechanical ventilation, varied substantially. The average time to presentation with pneumonia is 5.88 days, and may be linked to testing at hospitalisation; fever is often reported at onset (where the mean time to develop fever is 0.77 days).
- Published
- 2020
- Full Text
- View/download PDF
24. Report 7: Estimating infection prevalence in Wuhan City from repatriation flights
- Author
-
Thompson, H, Imai, N, Dighe, A, Baguelin, M, Bhatia, S, Boonyasiri, A, Cori, A, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Dorigatti, I, Fitzjohn, R, Fu, H, Gaythorpe, K, Ghani, A, Green, W, Hamlet, A, Hinsley, W, Laydon, D, Nedjati Gilani, G, Okell, L, Riley, S, Van Elsland, S, Volz, E, Wang, H, Yuanrong, W, Whittaker, C, Xi, X, Donnelly, C, Ferguson, N, and Medical Research Council (MRC)
- Subjects
Coronavirus ,Prevalence ,COVID-19 ,Repatriation flights ,health care economics and organizations - Abstract
Since the end of January 2020, in response to the growing COVID-19 epidemic, 55 countries have repatriated over 8000 citizens from Wuhan City, China. In addition to quarantine measures for returning citizens, many countries implemented PCR screening to test for infection regardless of symptoms. These flights therefore give estimates of infection prevalence in Wuhan over time. Between 30th January and 1st February (close to the peak of the epidemic in Wuhan), infection prevalence was 0.87% (95% CI: 0.32% - 1.89%). As countries now start to repatriate citizens from Iran and northern Italy, information from repatriated citizens could help inform the level of response necessary to help control the outbreaks unfolding in newly affected areas.
- Published
- 2020
25. Report 6: Relative sensitivity of international surveillance
- Author
-
Bhatia, S, Imai, N, Cuomo-Dannenburg, G, Baguelin, M, Boonyasiri, A, Cori, A, Cucunuba Perez, Z, Dorigatti, I, Fitzjohn, R, Fu, H, Gaythorpe, K, Ghani, A, Hamlet, A, Hinsley, W, Laydon, D, Nedjati Gilani, G, Thompson, H, Okell, L, Riley, S, Van Elsland, S, Volz, E, Wang, H, Wang, Y, Whittaker, C, Xi, X, Donnelly, C, Ferguson, N, and Medical Research Council (MRC)
- Subjects
Surveillance ,COVID-19 - Abstract
Since the start of the COVID-19 epidemic in late 2019, there are now 29 affected countries with over 1000 confirmed cases outside of mainland China. In previous reports, we estimated the likely epidemic size in Wuhan City based on air traffic volumes and the number of detected cases internationally. Here we analysed COVID-19 cases exported from mainland China to different regions and countries, comparing the country-specific rates of detected and confirmed cases per flight volume to estimate the relative sensitivity of surveillance in different countries. Although travel restrictions from Wuhan City and other cities across China may have reduced the absolute number of travellers to and from China, we estimated that about two thirds of COVID-19 cases exported from mainland China have remained undetected worldwide, potentially resulting in multiple chains of as yet undetected human-to-human transmission outside mainland China.
- Published
- 2020
26. Report 5: Phylogenetic analysis of SARS-CoV-2
- Author
-
Volz, E, Baguelin, M, Bhatia, S, Boonyasiri, A, Cori, A, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Donnelly, C, Dorigatti, I, Fitzjohn, R, Fu, H, Gaythorpe, K, Ghani, A, Hamlet, A, Hinsley, W, Imai, N, Laydon, D, Nedjati Gilani, G, Okell, L, Riley, S, Van Elsland, S, Wang, H, Wang, Y, Xi, X, Ferguson, N, Medical Research Council (MRC), and The Royal Society
- Subjects
Phylogenetics ,COVID-19 - Abstract
Genetic diversity of SARS-CoV-2 (formerly 2019-nCoV), the virus which causes COVID-19, provides information about epidemic origins and the rate of epidemic growth. By analysing 53 SARS-CoV-2 whole genome sequences collected up to February 3, 2020, we find a strong association between the time of sample collection and accumulation of genetic diversity. Bayesian and maximum likelihood phylogenetic methods indicate that the virus was introduced into the human population in early December and has an epidemic doubling time of approximately seven days. Phylodynamic modelling provides an estimate of epidemic size through time. Precise estimates of epidemic size are not possible with current genetic data, but our analyses indicate evidence of substantial heterogeneity in the number of secondary infections caused by each case, as indicated by a high level of over-dispersion in the reproduction number. Larger numbers of more systematically sampled sequences – particularly from across China – will allow phylogenetic estimates of epidemic size and growth rate to be substantially refined.
- Published
- 2020
- Full Text
- View/download PDF
27. Report 4: Severity of 2019-novel coronavirus (nCoV)
- Author
-
Dorigatti, I, Okell, L, Cori, A, Imai, N, Baguelin, M, Bhatia, S, Boonyasiri, A, Cucunuba Perez, Z, Cuomo-Dannenburg, G, Fitzjohn, R, Fu, H, Gaythorpe, K, Hamlet, A, Hinsley, W, Hong, N, Kwun, M, Laydon, D, Nedjati Gilani, G, Riley, S, Van Elsland, S, Volz, E, Wang, H, Walters, C, Xi, X, Donnelly, C, Ghani, A, Ferguson, N, Medical Research Council (MRC), and The Royal Society
- Subjects
CFR ,COVID-19 ,Severity - Abstract
We present case fatality ratio (CFR) estimates for three strata of 2019-nCoV infections. For cases detected in Hubei, we estimate the CFR to be 18% (95% credible interval: 11%-81%). For cases detected in travellers outside mainland China, we obtain central estimates of the CFR in the range 1.2-5.6% depending on the statistical methods, with substantial uncertainty around these central values. Using estimates of underlying infection prevalence in Wuhan at the end of January derived from testing of passengers on repatriation flights to Japan and Germany, we adjusted the estimates of CFR from either the early epidemic in Hubei Province, or from cases reported outside mainland China, to obtain estimates of the overall CFR in all infections (asymptomatic or symptomatic) of approximately 1% (95% confidence interval 0.5%-4%). It is important to note that the differences in these estimates does not reflect underlying differences in disease severity between countries. CFRs seen in individual countries will vary depending on the sensitivity of different surveillance systems to detect cases of differing levels of severity and the clinical care offered to severely ill cases. All CFR estimates should be viewed cautiously at the current time as the sensitivity of surveillance of both deaths and cases in mainland China is unclear. Furthermore, all estimates rely on limited data on the typical time intervals from symptom onset to death or recovery which influences the CFR estimates.
- Published
- 2020
28. Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study
- Author
-
Brady, O, Slater, H, Pemberton-Ross, P, Wenger, E, Maude, R, Ghani, A, Penny, M, Gerardin, J, White, L, Chitnis, N, Aguas, R, Hay, S, Smith, D, Stuckey, E, Okiro, E, Smith, T, Okell, L, Medical Research Council (MRC), and Bill & Melinda Gates Foundation
- Subjects
AFRICA ,Science & Technology ,HOST ,Consensus ,STRATEGIES ,TRANSMISSION ,LYMPHATIC FILARIASIS ,Articles ,PIPERAQUINE ,Malaria ,CAMPAIGNS ,Humans ,BURDEN ,Life Sciences & Biomedicine ,Public, Environmental & Occupational Health ,INTERVENTIONS - Abstract
Background Mass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some settings. We used consensus modelling to understand how to optimise the effects of mass drug administration in areas with low malaria transmission. Methods We collaborated with researchers doing field trials to establish a standard intervention scenario and standard transmission setting, and we input these parameters into four previously published models. We then varied the number of rounds of mass drug administration, coverage, duration, timing, importation of infection, and pre-administration transmission levels. The outcome of interest was the percentage reduction in annual mean prevalence of P falciparum parasite rate as measured by PCR in the third year after the final round of mass drug administration. Findings The models predicted differing magnitude of the effects of mass drug administration, but consensus answers were reached for several factors. Mass drug administration was predicted to reduce transmission over a longer timescale than accounted for by the prophylactic effect alone. Percentage reduction in transmission was predicted to be higher and last longer at lower baseline transmission levels. Reduction in transmission resulting from mass drug administration was predicted to be temporary, and in the absence of scale-up of other interventions, such as vector control, transmission would return to pre-administration levels. The proportion of the population treated in a year was a key determinant of simulated effectiveness, irrespective of whether people are treated through high coverage in a single round or new individuals are reached by implementation of several rounds. Mass drug administration was predicted to be more effective if continued over 2 years rather than 1 year, and if done at the time of year when transmission is lowest. Interpretation Mass drug administration has the potential to reduce transmission for a limited time, but is not an effective replacement for existing vector control. Unless elimination is achieved, mass drug administration has to be repeated regularly for sustained effect.
- Published
- 2017
29. Offspring birth weight, gestational age and maternal characteristics in relation to glucose status at age 53 years: evidence from a national birth cohort
- Author
-
Kuh, D., Mishra, G. D., Black, S., Lawlor, D. A., Smith, G. Davey, Okell, L., Wadsworth, M., and Hardy, R.
- Published
- 2008
30. The effect of delayed treatment on progression to severe Plasmodium falciparum malaria : a pooled multicentre individual-patient analysis
- Author
-
Mousa, A., Challenger, J. D., Cunnington, A. J., Al-Taiar, A., Anstey, N. M., Badaut, C., Barber, B. E., Datta, D., Drakeley, C., Griffin, J. T., Grigg, M. J., John, C. C., Migot Nabias, Florence, Reyburn, H., Riley, E. M., Sutherland, C. J., Viwami, F., Whitty, C. J., William, T., Ghani, A. C., and Okell, L. C.
- Published
- 2019
31. Insecticide-treated bednets for the prevention of Plasmodium falciparum malaria in Cambodia: a cluster-randomized trial
- Author
-
Sochantha, T., Hewitt, S., Nguon, C., Okell, L., Alexander, N., Yeung, S., Vannara, H., Rowland, M., and Socheat, D.
- Published
- 2006
32. Impact of Plasmodium falciparum Sulphadoxine-Pyrimethamine Resistance on the Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy in Africa: A Systematic Review and Meta-Analysis
- Author
-
Van Eijk, AM, Larsen, D, Kayentao, K, Koshy, G, Slaughter, D, Roper, C, Okell, L, Desai, M, Gutman, J, Khairallah, C, Rogerson, S, Sibley, C, Meshnick, S, Taylor, S, Ter Kuile, F, Medical Research Council (MRC), Medicines for Malaria Venture, and The Royal Society
- Subjects
1108 Medical Microbiology ,parasitic diseases ,1103 Clinical Sciences ,Microbiology - Abstract
Background Plasmodium falciparum resistance to sulphadoxine-pyrimethamine (SP) threatens the efficacy of intermittent preventive treatment (IPTp) for malaria in pregnancy in Africa. We conducted a meta-analysis to assess the impact of SP resistance on IPTp-SP effectiveness. Methods We searched databases (1990 to March-01-2018) for clinical studies (aggregated data) or surveys (individual-participant data) containing information on low birthweight (LBW, primary outcome) and malaria by IPTp-SP dose, and for studies reporting SP-resistance molecular markers. We performed random-effects meta-analysis (clinical studies) or multivariate log-binomial regression (surveys) to obtain summarized dose-response data (Relative-Risk-Reduction:RRR) and multivariate meta-regression to explore modifying effects of SP-resistance (dhps substitutions A437G, K540E, A581G). Findings Of 1097 records, 57 studies were included in the aggregated-data meta-analysis (59,457 births). The RRR for LBW declined with increasing prevalence of Pfdhps-K540E (P-trend=0.0060) but not with Pfdhps-A437G (P-trend=0.35). The RRR in areas of high (Pfdhps-K540E >90%, n=11), moderate (Central/West Africa:Pfdhps-A437G≥90% or East/southern Africa:Pfdhps-K540E 30-90%, n=16) and low SP-resistances (n=30) were 7% (95% CI 0-13), 21% (14-29) and 27% (21-33) respectively (P-trend=0.0054, I2=69.5%). In the individual-participant analysis of 13 surveys (42,394 births), IPTp-SP was associated with reduced LBW in areas with Pfdhps-K540E>90% & Pfdhps-A581G=10% (pooled Pfdhps-A581G prevalence:37%, range 29-46) (RRR=0.5%, -16-14, n=3). Interpretation The effectiveness of IPTp-SP is reduced in areas with high SP-resistance, but IPTp-SP remains associated with reduced LBW in areas where Pfdhps-K540E prevalence exceeds 90%. IPTp-SP is not effective in areas with ≥37% prevalence of the highly-resistant sextuple Pfdhps-A581G-containing genotype.
- Published
- 2018
33. Generating the evidence base for malaria elimination: the situation in Haiti
- Author
-
Okell, L C, primary and Churcher, T S, additional
- Published
- 2017
- Full Text
- View/download PDF
34. Asymptomatic malaria infections: detectability, transmissibility and public health relevance
- Author
-
Bousema, T., Okell, L., Felger, I., Drakeley, C., Bousema, T., Okell, L., Felger, I., and Drakeley, C.
- Abstract
Item does not contain fulltext, Most Plasmodium falciparum infections that are detected in community surveys are characterized by low-density parasitaemia and the absence of clinical symptoms. Molecular diagnostics have shown that this asymptomatic parasitic reservoir is more widespread than previously thought, even in low-endemic areas. In this Opinion article, we describe the detectability of asymptomatic malaria infections and the relevance of submicroscopic infections for parasite transmission to mosquitoes and for community interventions that aim at reducing transmission. We argue that wider deployment of molecular diagnostic tools is needed to provide adequate insight into the epidemiology of malaria and infection dynamics to aid elimination efforts.
- Published
- 2014
35. Residual Plasmodium falciparum Parasitemia in Kenyan Children After Artemisinin-Combination Therapy Is Associated With Increased Transmission to Mosquitoes and Parasite Recurrence.
- Author
-
Beshir, K.B., Sutherland, C.J., Sawa, P., Drakeley, C.J., Okell, L., Mweresa, C.K., Omar, S.A., Shekalaghe, S.A., Kaur, H., Ndaro, A., Chilongola, J., Schallig, H.D., Sauerwein, R.W., Hallett, R.L., Bousema, T., Beshir, K.B., Sutherland, C.J., Sawa, P., Drakeley, C.J., Okell, L., Mweresa, C.K., Omar, S.A., Shekalaghe, S.A., Kaur, H., Ndaro, A., Chilongola, J., Schallig, H.D., Sauerwein, R.W., Hallett, R.L., and Bousema, T.
- Abstract
Item does not contain fulltext
- Published
- 2013
36. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial
- Author
-
Sawa, P., Shekalaghe, S., Drakeley, C., Sutherland, C.J., Mweresa, C.K., Baidjoe, A.Y., Manjurano, A., Kavishe, R.A., Beshir, K.B., Yussuf, R.U., Omar, S.A., Hermsen, C.C., Okell, L., Schallig, H.D., Sauerwein, R.W., Hallett, R.L., Bousema, T., Sawa, P., Shekalaghe, S., Drakeley, C., Sutherland, C.J., Mweresa, C.K., Baidjoe, A.Y., Manjurano, A., Kavishe, R.A., Beshir, K.B., Yussuf, R.U., Omar, S.A., Hermsen, C.C., Okell, L., Schallig, H.D., Sauerwein, R.W., Hallett, R.L., and Bousema, T.
- Abstract
Item does not contain fulltext, BACKGROUND: Artemisinin-based combination therapy (ACT) reduces the potential for malaria transmission, compared with non-ACTs. It is unclear whether this effect differs between ACTs. METHODS: A total of 298 children (age, 6 months to 10 years) with uncomplicated falciparum malaria were randomized to artemether-lumefantrine (AL; n = 153) or dihydroartemisinin-piperaquine (DP; n = 145) in Mbita, a community in western Kenya. Gametocyte carriage was determined by molecular methods on days 0, 1, 2, 3, 7, 14, 28, and 42 after treatment initiation. The gametocyte infectiousness to mosquitoes was determined by mosquito-feeding assays on day 7 after beginning therapy. RESULTS: The cumulative risk of recurrent parasitemia on day 42 after initiation of treatment, unadjusted by polymerase chain reaction findings, was 20.7% (95% confidence interval [CI], 14.4-28.2) for AL, compared with 3.7% (95% CI, 1.2-8.5) for DP (P < .001). The mean duration of gametocyte carriage was 5.5 days (95% CI, 3.6-8.5) for AL and 15.3 days (95% CI, 9.7-24.2) for DP (P = .001). The proportion of mosquitoes that became infected after feeding on blood from AL-treated children was 1.88% (43 of 2293), compared with 3.50% (83 of 2371) for those that fed on blood from DP-treated children (P = .06); the oocyst burden among mosquitoes was lower among those that fed on blood from AL-treated children (P = .005) CONCLUSIONS: While DP was associated with a longer prophylactic time after treatment, gametocyte carriage and malaria transmission to mosquitoes was lower after AL treatment. CLINICAL TRIALS REGISTRATION: NCT00868465.
- Published
- 2013
37. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control.
- Author
-
Okell, L., Bousema, J.T., Griffin, J.T., Ouedraogo, A.L., Ghani, A., Drakeley, C., Okell, L., Bousema, J.T., Griffin, J.T., Ouedraogo, A.L., Ghani, A., and Drakeley, C.
- Abstract
Contains fulltext : 107879.pdf (publisher's version ) (Open Access)
- Published
- 2012
38. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania
- Author
-
Shekalaghe, S., Drakeley, C., Bosch, S. van den, Braak, R. ter, Bijllaardt, W. van den, Mwanziva, C., Semvua, S., Masokoto, A., Mosha, F., Teelen, K.A.E.M., Hermsen, R., Okell, L., Gosling, R., Sauerwein, R.W., Bousema, T., Shekalaghe, S., Drakeley, C., Bosch, S. van den, Braak, R. ter, Bijllaardt, W. van den, Mwanziva, C., Semvua, S., Masokoto, A., Mosha, F., Teelen, K.A.E.M., Hermsen, R., Okell, L., Gosling, R., Sauerwein, R.W., and Bousema, T.
- Abstract
Contains fulltext : 96570.pdf (publisher's version ) (Open Access), BACKGROUND: Effective mass drug administration (MDA) with anti-malarial drugs can clear the human infectious reservoir for malaria and thereby interrupt malaria transmission. The likelihood of success of MDA depends on the intensity and seasonality of malaria transmission, the efficacy of the intervention in rapidly clearing all malaria parasite stages and the degree to which symptomatic and asymptomatic parasite carriers participate in the intervention. The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP) plus artesunate (AS) plus primaquine (PQ, single dose 0.75 mg/kg) on malaria transmission was determined in an area of very low and seasonal malaria transmission in northern Tanzania. METHODS: In a cluster-randomized trial in four villages in Lower Moshi, Tanzania, eight clusters (1,110 individuals; cluster size 47- 209) were randomized to observed treatment with SP+AS+PQ and eight clusters (2,347 individuals, cluster size 55- 737) to treatment with placebo over three days. Intervention and control clusters were 1 km apart; households that were located between clusters were treated as buffer zones where all individuals received SP+AS+PQ but were not selected for the evaluation. Passive case detection was done for the entire cohort and active case detection in 149 children aged 1-10 year from the intervention arm and 143 from the control arm. Four cross-sectional surveys assessed parasite carriage by microscopy and molecular methods during a five-month follow-up period. RESULTS: The coverage rate in the intervention arm was 93.0% (1,117/1,201). Parasite prevalence by molecular detection methods was 2.2-2.7% prior to the intervention and undetectable during follow-up in both the control and intervention clusters. None of the slides collected during cross-sectional surveys had microscopically detectable parasite densities. Three clinical malaria episodes occurred in the intervention (n = 1) and control clusters (n = 2). CONCLUSI
- Published
- 2011
39. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs.
- Author
-
Bousema, T., Okell, L., Shekalaghe, S., Griffin, J.T., Omar, S., Sawa, P., Sutherland, C., Sauerwein, R.W., Ghani, A.C., Drakeley, C., Bousema, T., Okell, L., Shekalaghe, S., Griffin, J.T., Omar, S., Sawa, P., Sutherland, C., Sauerwein, R.W., Ghani, A.C., and Drakeley, C.
- Abstract
Contains fulltext : 89379.pdf (publisher's version ) (Open Access), BACKGROUND: There is renewed acknowledgement that targeting gametocytes is essential for malaria control and elimination efforts. Simple mathematical models were fitted to data from clinical trials in order to determine the mean gametocyte circulation time and duration of gametocyte carriage in treated malaria patients. METHODS: Data were used from clinical trials from East Africa. The first trial compared non-artemisinin combination therapy (non-ACT: sulphadoxine-pyrimethamine (SP) plus amodiaquine) and artemisinin-based combination therapy (ACT: SP plus artesunate (AS) or artemether-lumefantrine). The second trial compared ACT (SP+AS) with ACT in combination with a single dose of primaquine (ACT-PQ: SP+AS+PQ). Mature gametocytes were quantified in peripheral blood samples by nucleic acid sequence based amplification. A simple deterministic compartmental model was fitted to gametocyte densities to estimate the circulation time per gametocyte; a similar model was fitted to gametocyte prevalences to estimate the duration of gametocyte carriage after efficacious treatment. RESULTS: The mean circulation time of gametocytes was 4.6-6.5 days. After non-ACT treatment, patients were estimated to carry gametocytes for an average of 55 days (95% CI 28.7 - 107.7). ACT reduced the duration of gametocyte carriage fourfold to 13.4 days (95% CI 10.2-17.5). Addition of PQ to ACT resulted in a further fourfold reduction of the duration of gametocyte carriage. CONCLUSIONS: These findings confirm previous estimates of the circulation time of gametocytes, but indicate a much longer duration of (low density) gametocyte carriage after apparently successful clearance of asexual parasites. ACT shortened the period of gametocyte carriage considerably, and had the most pronounced effect on mature gametocytes when combined with PQ.
- Published
- 2010
40. Developmental Origins of Midlife Grip Strength: Findings From a Birth Cohort Study
- Author
-
Kuh, D., primary, Hardy, R., additional, Butterworth, S., additional, Okell, L., additional, Wadsworth, M., additional, Cooper, C., additional, and Aihie Sayer, A., additional
- Published
- 2006
- Full Text
- View/download PDF
41. From intervention to impact: modelling the potential mortality impact achievable by different long-lasting, insecticide-treated net delivery strategies
- Author
-
Okell Lucy C, Paintain Lucy, Webster Jayne, Hanson Kara, and Lines Jo
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background The current target of universal access to long-lasting, insecticide-treated nets (LLIN) is 80% coverage to reduce malaria deaths by 75% by 2015. So far, campaigns have been the main channel for large-scale delivery of LLINs, however the World Health Organization has recommended that equal priority should be given to delivery via routine antenatal care (ANC) and immunization systems (EPI) to target pregnant women and children from birth. These various channels of LLIN delivery are targeted to children of different ages. Since risk of mortality varies with child age and LLIN effectiveness declines with net age, it was hypothesized that the age at which a child receives a new LLIN, and therefore the delivery channel, is important in optimizing the health impact of a net. Methods A simple dynamic mathematical model was developed of delivery and impact of LLINs among children under five years of age and their household members, incorporating data on age-specific malaria death rates, net use by household structure, and net efficacy over time. Results The presented analysis finds that supplementing a universal mass campaign with extra ANC delivery would achieve a 1.4 times higher mortality reduction than campaign delivery alone, reflecting that children born in the years between campaigns would otherwise have access to old nets or no nets at an age of high risk. The relative advantage of supplementary ANC delivery is still present though smaller if malaria transmission levels are lower or if there is a strong mass effect achieved by mass campaigns. Conclusion These results indicate that LLIN delivery policies must take into account the age of greatest malaria risk. Emphasis should be placed on supporting routine delivery of LLINs to young children as well as campaigns.
- Published
- 2012
- Full Text
- View/download PDF
42. Association of sub-microscopic malaria parasite carriage with transmission intensity in north-eastern Tanzania
- Author
-
Manjurano Alphaxard, Okell Lucy, Lukindo Tedson, Reyburn Hugh, Olomi Raimos, Roper Cally, Clark Taane G, Joseph Sarah, Riley Eleanor M, and Drakeley Chris
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background In malaria endemic areas, individuals are frequently asymptomatic and may be undetected by conventional microscopy or newer, rapid diagnostic tests. Molecular techniques allow a more accurate assessment of this asymptomatic parasite burden, the extent of which is important for malaria control. This study examines the relative prevalence of sub-microscopic level parasite carriage and clonal complexity of infections (multiplicity of infection) over a range of endemicities in a region of north-eastern Tanzania where altitude is an established proxy of malaria transmission. The PCR prevalence was then compared against other measures of transmission intensity collected in the same area. Methods This study used 1,121 blood samples collected from a previously conducted cross-sectional malario-metric survey during the short rainy season in 2001 from 13 villages (three at < 600 m, four at 600-1,200 m and six at > 1,200 m in altitude above sea level). Samples were analysed by PCR for carriage of parasites and multiplicity of infection. These data were compared with other measures of transmission intensity collected from the same area. Results Parasite prevalence was 34.7% by PCR and 13.6% by microscopy; a 2.5-fold difference in line with other recent observations. This fold difference was relatively consistent at the different altitude bands despite a marked decrease in parasite prevalence with altitude: < 600 m 70.9 vs 28.6, 600-1,200 m 35.5 vs 9.9, > 1,200 m 15.8 vs 5.9. The difference between parasite prevalence by PCR was 3.2 in individuals aged between 15 and 45 years (34.5 vs 10.9) compared with 2.5 in those aged 1-5 (34.0 vs 13.5) though this was not statistically significant. Multiplicity of infection (MOI) ranged from 1.2 to 3.7 and was positively associated with parasite prevalence assessed by both PCR and microscopy. There was no association of MOI and age. Village level PCR parasite prevalence was strongly correlated with altitude, sero-conversion rate and predicted entomological inoculation rate. Conclusions Asymptomatic, low density, multi-clone malaria infection was common in this study area. These infections are important as potential contributors to the infectious reservoir of parasites and need to be identified by control programmes especially in this era where malaria elimination is a focus. High throughput standardized PCR approaches are needed to identify individuals who are malaria carriers.
- Published
- 2011
- Full Text
- View/download PDF
43. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania
- Author
-
Shekalaghe Seif A, Drakeley Chris, van den Bosch Sven, ter Braak Roel, van den Bijllaardt Wouter, Mwanziva Charles, Semvua Salimu, Masokoto Alutu, Mosha Frank, Teelen Karina, Hermsen Rob, Okell Lucy, Gosling Roly, Sauerwein Robert, and Bousema Teun
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Effective mass drug administration (MDA) with anti-malarial drugs can clear the human infectious reservoir for malaria and thereby interrupt malaria transmission. The likelihood of success of MDA depends on the intensity and seasonality of malaria transmission, the efficacy of the intervention in rapidly clearing all malaria parasite stages and the degree to which symptomatic and asymptomatic parasite carriers participate in the intervention. The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP) plus artesunate (AS) plus primaquine (PQ, single dose 0.75 mg/kg) on malaria transmission was determined in an area of very low and seasonal malaria transmission in northern Tanzania. Methods In a cluster-randomized trial in four villages in Lower Moshi, Tanzania, eight clusters (1,110 individuals; cluster size 47- 209) were randomized to observed treatment with SP+AS+PQ and eight clusters (2,347 individuals, cluster size 55- 737) to treatment with placebo over three days. Intervention and control clusters were 1km apart; households that were located between clusters were treated as buffer zones where all individuals received SP+AS+PQ but were not selected for the evaluation. Passive case detection was done for the entire cohort and active case detection in 149 children aged 1-10 year from the intervention arm and 143 from the control arm. Four cross-sectional surveys assessed parasite carriage by microscopy and molecular methods during a five-month follow-up period. Results The coverage rate in the intervention arm was 93.0% (1,117/1,201). Parasite prevalence by molecular detection methods was 2.2-2.7% prior to the intervention and undetectable during follow-up in both the control and intervention clusters. None of the slides collected during cross-sectional surveys had microscopically detectable parasite densities. Three clinical malaria episodes occurred in the intervention (n = 1) and control clusters (n = 2). Conclusions This study illustrates the possibility to achieve high coverage with a three-day intervention but also the difficulty in defining suitable outcome measures to evaluate interventions in areas of very low malaria transmission intensity. The decline in transmission intensity prior to the intervention made it impossible to assess the impact of MDA in the chosen study setting. Trial Registration ClinicalTrials.gov: NCT00509015
- Published
- 2011
- Full Text
- View/download PDF
44. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs
- Author
-
Sawa Patrick, Omar Sabah, Griffin Jamie T, Shekalaghe Seif, Okell Lucy, Bousema Teun, Sutherland Colin, Sauerwein Robert, Ghani Azra C, and Drakeley Chris
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background There is renewed acknowledgement that targeting gametocytes is essential for malaria control and elimination efforts. Simple mathematical models were fitted to data from clinical trials in order to determine the mean gametocyte circulation time and duration of gametocyte carriage in treated malaria patients. Methods Data were used from clinical trials from East Africa. The first trial compared non-artemisinin combination therapy (non-ACT: sulphadoxine-pyrimethamine (SP) plus amodiaquine) and artemisinin-based combination therapy (ACT: SP plus artesunate (AS) or artemether-lumefantrine). The second trial compared ACT (SP+AS) with ACT in combination with a single dose of primaquine (ACT-PQ: SP+AS+PQ). Mature gametocytes were quantified in peripheral blood samples by nucleic acid sequence based amplification. A simple deterministic compartmental model was fitted to gametocyte densities to estimate the circulation time per gametocyte; a similar model was fitted to gametocyte prevalences to estimate the duration of gametocyte carriage after efficacious treatment. Results The mean circulation time of gametocytes was 4.6-6.5 days. After non-ACT treatment, patients were estimated to carry gametocytes for an average of 55 days (95% CI 28.7 - 107.7). ACT reduced the duration of gametocyte carriage fourfold to 13.4 days (95% CI 10.2-17.5). Addition of PQ to ACT resulted in a further fourfold reduction of the duration of gametocyte carriage. Conclusions These findings confirm previous estimates of the circulation time of gametocytes, but indicate a much longer duration of (low density) gametocyte carriage after apparently successful clearance of asexual parasites. ACT shortened the period of gametocyte carriage considerably, and had the most pronounced effect on mature gametocytes when combined with PQ.
- Published
- 2010
- Full Text
- View/download PDF
45. Sub-microscopic malaria cases and mixed malaria infection in a remote area of high malaria endemicity in Rattanakiri province, Cambodia: implication for malaria elimination
- Author
-
Socheat Duong, Chou Monidarin, Hewitt Sean, Chy Sophy, Incardona Sandra, Duval Linda, Jeanne Isabelle, Okell Lucy, Rogers William O, Steenkeste Nicolas, Babin François-Xavier, Ariey Frédéric, and Rogier Christophe
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Malaria microscopy and rapid diagnostic tests are insensitive for very low-density parasitaemia. This insensitivity may lead to missed asymptomatic sub-microscopic parasitaemia, a potential reservoir for infection. Similarly, mixed infections and interactions between Plasmodium species may be missed. The objectives were first to develop a rapid and sensitive PCR-based diagnostic method to detect low parasitaemia and mixed infections, and then to investigate the epidemiological importance of sub-microscopic and mixed infections in Rattanakiri Province, Cambodia. Methods A new malaria diagnostic method, using restriction fragment length polymorphism analysis of the cytochrome b genes of the four human Plasmodium species and denaturing high performance liquid chromatography, has been developed. The results of this RFLP-dHPLC method have been compared to 1) traditional nested PCR amplification of the 18S rRNA gene, 2) sequencing of the amplified fragments of the cytochrome b gene and 3) microscopy. Blood spots on filter paper and Giemsa-stained blood thick smears collected in 2001 from 1,356 inhabitants of eight villages of Rattanakiri Province have been analysed by the RFLP-dHPLC method and microscopy to assess the prevalence of sub-microscopic and mixed infections. Results The sensitivity and specificity of the new RFLP-dHPLC was similar to that of the other molecular methods. The RFLP-dHPLC method was more sensitive and specific than microscopy, particularly for detecting low-level parasitaemia and mixed infections. In Rattanakiri Province, the prevalences of Plasmodium falciparum and Plasmodium vivax were approximately two-fold and three-fold higher, respectively, by RFLP-dHPLC (59% and 15%, respectively) than by microscopy (28% and 5%, respectively). In addition, Plasmodium ovale and Plasmodium malariae were never detected by microscopy, while they were detected by RFLP-dHPLC, in 11.2% and 1.3% of the blood samples, respectively. Moreover, the proportion of mixed infections detected by RFLP-dHPLC was higher (23%) than with microscopy (8%). Conclusions The rapid and sensitive molecular diagnosis method developed here could be considered for mass screening and ACT treatment of inhabitants of low-endemicity areas of Southeast Asia.
- Published
- 2010
- Full Text
- View/download PDF
46. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials
- Author
-
Bousema Teun, Ghani Azra C, Drakeley Chris J, Okell Lucy C, and Sutherland Colin J
- Subjects
Arctic medicine. Tropical medicine ,RC955-962 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Artemisinin combination therapies (ACT), which are increasingly being introduced for treatment of Plasmodium falciparum malaria, are more effective against sexual stage parasites (gametocytes) than previous first-line antimalarials and therefore have the potential to reduce parasite transmission. The size of this effect is estimated in symptomatic P. falciparum infections. Methods Data on 3,174 patients were pooled from six antimalarial trials conducted in The Gambia and Kenya. Multivariable regression was used to investigate the role of ACT versus non-artemisinin antimalarial treatment, treatment failure, presence of pre-treatment gametocytes and submicroscopic gametocytaemia on transmission to mosquitoes and the area under the curve (AUC) of gametocyte density during the 28 days of follow up. Results ACT treatment was associated with a significant reduction in the probability of being gametocytaemic on the day of transmission experiments (OR 0.20 95% CI 0.16–0.26), transmission to mosquitoes by slide-positive gametocyte carriers (OR mosquito infection 0.49 95% CI 0.33–0.73) and AUC of gametocyte density (ratio of means 0.35 95% CI 0.31–0.41). Parasitological treatment failure did not account for the difference between ACT and non-artemisinin impact. The presence of slide-positive gametocytaemia prior to treatment significantly reduced ACT impact on gametocytaemia (p < 0.001). Taking account of submicroscopic gametocytaemia reduced estimates of ACT impact in a high transmission setting in Kenya, but not in a lower transmission setting in the Gambia. Conclusion Treatment with ACT significantly reduces infectiousness of individual patients with uncomplicated falciparum malaria compared to previous first line treatments. Rapid treatment of cases before gametocytaemia is well developed may enhance the impact of ACT on transmission.
- Published
- 2008
- Full Text
- View/download PDF
47. Cost of treating severe malaria in children in Africa: a systematic literature review.
- Author
-
Mori AT, Mallange G, Kühl MJ, and Okell L
- Subjects
- Child, Child, Preschool, Humans, Infant, Africa, Antimalarials economics, Antimalarials therapeutic use, Cost of Illness, Health Care Costs statistics & numerical data, Infant, Newborn, Malaria diagnosis, Malaria drug therapy, Malaria economics
- Abstract
Background: Malaria is a major cause of ill health and death in children in Africa. The disease also imposes a severe social and economic burden on households and health systems and is strongly associated with poverty. This study summarizes the most up-to-date cost of treating severe malaria in children in Africa., Methods: A systematic search was conducted in PubMed, Embase, Cinahl, and Web of Science databases. Google and Google Scholar were searched for grey literature followed by scanning of the reference lists of the previous systematic reviews. The search was limited to children < 12 years, malaria-endemic countries in Africa, and the English language. All costs were adjusted to the year 2023., Results: 19 studies conducted in 12 countries were identified: 14 reported provider costs, and 11 household costs. Out of the 19 studies found, 11 were published before 2018 while 11 reported data that are currently more than ten years old. Studies varied methodologically and in the scope of resources included to estimate the cost. The provider costs ranged from USD 27 in Uganda to USD 165 per patient in Kenya (median value USD 90), while household costs ranged from USD 13 in Kenya to USD 245 per patient in Gabon (median value USD 50). All identified household malaria treatment costs except one represented catastrophic health expenditure, making out more than 10% of the monthly Gross National Income per capita in the respective countries., Conclusion: Evidence on the cost of treating severe malaria in children in Africa is scarce. However, the few existing studies show that severe malaria in children imposes a significant economic burden on the providers and households. More studies are needed, particularly in high-burden high-impact countries, to inform resource allocation decisions., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
48. The private market for antimicrobials: an exploration of two selected mining and frontier areas of Guyana.
- Author
-
Cox H, Roeder F, Okell L, Niles-Robin R, James K, Valz O, Hauck K, and Sicuri E
- Abstract
Objective: To identify challenges that may raise pathogens' resistance to antimicrobial drugs by exploring the private market for antimicrobials in two selected mining and frontier areas of Guyana., Methods: The private sector supply was mapped by approaching all authorized pharmacies and informal outlets, e.g., street vendors and grocery stores, around the two selected towns. Interviews were conducted with a) sellers on the availability of drugs, expiration dates, prices, and main producers; and b) customers on purchased drugs, diagnoses, and prescriptions received before purchasing drugs, and intention to complete the treatment. The information collected was described, and the determinants of the self-reported intention of customers to complete the whole treatment were identified., Results: From the perspective of the supply of antimicrobials, essential medicines faced low and insecure availability, and prescriptions frequently deviated from diagnoses. From the perspective of the demand for antimicrobials, one-third of purchased antibiotics had a high potential for antimicrobial resistance as per the World Health Organization AWaRe classification. A high price reduced the self-reported intention to complete the treatment among those who had a prescription, while buying the medication in a licensed pharmacy increased such intention., Conclusions: In Guyana, there persists a need to establish and revise policies addressing both supply and demand, such as restricting the sale of antimicrobials to licensed pharmacies and upon prescription, improving prescription practices while reducing the financial burden to patients, guaranteeing access to first-line treatment drugs, and instructing patients on appropriate use of antimicrobials. Revising such policies is an essential step to contain antimicrobial resistance in the analyzed areas and across Guyana., Competing Interests: Conflict of interest. None declared.
- Published
- 2024
- Full Text
- View/download PDF
49. Parasite clearance and protection from Plasmodium falciparum infection (PCPI): a three-arm, parallel, double-blinded, placebo-controlled, randomised trial of presumptive sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine plus amodiaquine versus artesunate monotherapy among asymptomatic children 3-5 years of age in Cameroon.
- Author
-
Martinez-Vega R, Mbacham WF, Ali I, Nji A, Mousa A, Beshir KB, Chopo-Pizarro A, Kaur H, Okell L, Hansson H, Hocke EF, Alifrangis M, Gosling R, Roper C, Sutherland C, and Chico RM
- Subjects
- Humans, Cameroon, Child, Preschool, Double-Blind Method, Female, Male, Artemisinins therapeutic use, Artemisinins administration & dosage, Treatment Outcome, Chemoprevention methods, Pyrimethamine therapeutic use, Pyrimethamine administration & dosage, Sulfadoxine therapeutic use, Sulfadoxine administration & dosage, Malaria, Falciparum prevention & control, Malaria, Falciparum drug therapy, Malaria, Falciparum parasitology, Antimalarials therapeutic use, Antimalarials administration & dosage, Amodiaquine therapeutic use, Drug Combinations, Plasmodium falciparum drug effects, Plasmodium falciparum genetics, Artesunate therapeutic use
- Abstract
Background: The World Health Organization 2022 malaria chemoprevention guidelines recommend providing a full course of antimalarial treatment at pre-defined intervals, regardless of malaria status to prevent illness among children resident in moderate to high perennial malaria transmission settings as perennial malaria chemoprevention (PMC) with sulfadoxine-pyrimethamine (SP). The dhps I431V mutation circulating in West Africa has unknown effect on SP protective efficacy., Methods: This protocol is for a three-arm, parallel, double-blinded, placebo-controlled, randomised trial in Cameroon among children randomly assigned to one of three directly-observed treatment groups: (i) Group 1 (n = 450) receives daily artesunate (AS) placebo on days - 7 to -1, then active SP plus placebo amodiaquine (AQ) on day 0, and placebo AQ on days 1 and 2; (ii) Group 2 (n = 250) receives placebo AS on days - 7 to -1, then active SP and AQ on day 0, and active AQ on days 1 and 2; and (iii) Group 3 (n = 200) receives active AS on days - 7 to -1, then placebo SP on day 0 and placebo AQ on days 0 to 2. On days 0, 2, 5, 7, and thereafter weekly until day 28, children provide blood for thick smear slides. Dried blood spots are collected on the same days and weekly from day 28 to day 63 for quantitative polymerase chain reaction (qPCR) and genotype analyses., Discussion: Our aim is to quantify the chemopreventive efficacy of SP, and SP plus AQ, and measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP chemoprevention. We will report unblinded results including: (i) time-to-parasite clearance among SP and SP plus AQ recipients who were positive on day 0 by qPCR and followed to day 63; (ii) mean duration of SP and SP plus AQ protection against infection, and (iii) mean duration of symptom-free status among SP and SP plus AQ recipients who were parasite free on day 0 by qPCR. Our study is designed to compare the 28-day follow-up of the new WHO malaria chemoprevention efficacy study protocol with extended follow-up to day 63., Trial Registration: ClinicalTrials.gov NCT06173206; 15/12/2023., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
50. Risk of selection and timelines for the continued spread of artemisinin and partner drug resistance in Africa.
- Author
-
Watson OJ, Muchiri S, Ward A, Meier-Sherling C, Asua V, Katairo T, Brewer T, Cuomo-Dannenburg G, Winskill P, Bailey JA, Okell L, Scudu G, and Woolsey AM
- Abstract
The introduction of artemisinin combination therapies (ACTs) has significantly reduced the burden of Plasmodium falciparum malaria, yet the emergence of artemisinin partial resistance (ART-R) as well as partner drug resistance threatens these gains. Recent confirmations of prevalent de novo ART-R mutations in Africa, in particular in Rwanda, Uganda and Ethiopia, underscore the urgency of addressing this issue in Africa. Our objective is to characterise this evolving resistance landscape in Africa and understand the speed with which ART-R will continue to spread. We produce estimates of both ART-R and partner drug resistance by bringing together WHO, WWARN and MalariaGen Pf7k data on antimalarial resistance in combination with a literature review. We integrate these estimates within a mathematical modelling approach, aincorporating to estimate parameters known to impact the selection of ART-R for each malaria-endemic country and explore scenarios of ART-R spread and establishment. We identify 16 malaria-endemic countries in Africa to prioritise for surveillance and future deployment of alternative antimalarial strategies, based on ART-R reaching greater than 10% prevalence by 2040 under current malaria burden and effective-treatment coverage. If resistance continues to spread at current rates with no change in drug policy, we predict that partner drug resistance will emerge and the mean percentage of treatment failure across Africa will reach 30.74% by 2060 (parameter uncertainty range: 24.98% - 34.54%). This translates to an alarming number of treatment failures, with 52,980,600 absolute cases of treatment failure predicted in 2060 in Africa (parameter uncertainty range: 26,374,200 - 93,672,400) based on current effective treatment coverage. Our results provide a refined and updated prediction model for the emergence of ART-R to help guide antimalarial policy and prioritise future surveillance efforts and innovation in Africa. These results put into stark context the speed with which antimalarial resistance may spread in Africa if left unchecked, confirming the need for swift and decisive action in formulating antimalarial treatment policies focused on furthering malaria control and containing antimalarial resistance in Africa. The rise of artemisinin partial resistance (ART-R) and increasing partner drug tolerance by Plasmodium falciparum malaria in Africa threatens to undo malaria control efforts. Recent confirmations of de novo ART-R markers in Rwanda, Uganda, and Ethiopia highlight the urgent need to address this threat in Africa, where the vast majority of cases and deaths occur. This study characterises the resistance landscape and predicts the spread of antimalarial resistance across Africa. We estimate and map the current levels of resistance markers related to artemisinin and its partner drugs using WHO, WWARN, and MalariaGen Pf7k data. We combine these estimates with current malaria transmission and treatment data and use an established individual-based model of malaria resistance to simulate future resistance spread. We identify 16 African countries at highest risk of ART-R for prioritisation of enhanced surveillance and alternative antimalarial strategies. We project that, without policy changes, ART-R will exceed 10% in these regions by 2040. By 2060, if resistance spreads unchecked, we predict mean treatment failure rates will reach 30.74% (parameter uncertainty range: 24.98% - 34.54%) across Africa. This alarming spread of resistance is predicted to cause 52.98 million treatment failures (uncertainty range: 26.37 million - 93.67 million) in 2060. The impact of antimalarial resistance in Africa, if left unchecked, would hugely damage efforts to reduce malaria burden. Our results underscore the critical need for swift policy action to contain resistance and guide future surveillance and intervention efforts., Competing Interests: Declaration of Interests OJW received personal consultancy fees from Clinton Health Access Initiative related to artemisinin resistance modelling.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.